Vaccine Institute & Division of Clinical Sciences, St. George's, University of London, Cranmer Terrace, London SW17 0RE, UK.
Expert Rev Vaccines. 2011 May;10(5):685-94. doi: 10.1586/erv.11.61.
Streptococcus agalactiae (group B streptococcus) is an important cause of disease in infants, pregnant women, the elderly and immunosuppressed adults. An effective vaccine is likely to prevent the majority of infant disease (both early and late onset), to avoid the limitations of intrapartum antibiotic prophylaxis and to be cost effective. A number of candidates, including capsular conjugate vaccines, have the potential to be successful vaccines. Phase II human studies with capsular conjugate vaccines have been completed successfully. Issues yet to be resolved include the safety and acceptability of vaccination during pregnancy, the durability of vaccine-derived immunity and the regulatory issues required for licensure.
无乳链球菌（B 组链球菌）是婴儿、孕妇、老年人和免疫抑制成年人疾病的重要病因。有效的疫苗可能预防大多数婴儿疾病（早发型和晚发型），避免了产时抗生素预防的局限性，并且具有成本效益。一些候选疫苗，包括荚膜结合疫苗，有可能成为成功的疫苗。用荚膜结合疫苗进行的 II 期人体研究已成功完成。尚未解决的问题包括在怀孕期间接种疫苗的安全性和可接受性、疫苗衍生免疫力的持久性以及获得许可所需的监管问题。
